Status:
ACTIVE_NOT_RECRUITING
Predictive Value of Albumin - Bilirubin Score and CRP - Albumin - Lymphocyte Index for HCC Prognosis After Radical Resection
Lead Sponsor:
Qiang Xu
Conditions:
Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma (HCC) Prognosis
Eligibility:
All Genders
18-80 years
Brief Summary
Evaluate the predictive value of the CALLY index and ALBI grading for the prognosis of patients with hepatocellular carcinoma (HCC) after radical resection, so as to provide a reference for clinical t...
Detailed Description
China bears a heavy burden of liver cancer. In 2022, there were 370,000 new cases and 320,000 deaths, ranking 4th in incidence and 2nd in mortality among malignant tumors. HCC, accounting for over 80%...
Eligibility Criteria
Inclusion
- (1) Age ≥ 18 years old (2) Postoperative pathological examination confirmed hepatocellular carcinoma (HCC) (3) No other anti-tumor treatment was received before surgery (4) Radical resection was performed, and the pathological examination under the microscope showed negative surgical margins.
Exclusion
- (1) Complicated with other malignant tumors. (2) Incomplete clinicopathological data and prognostic information. (3) Received preoperative anti-cancer treatment. (4) Follow-up less than 1 month after hepatectomy. (5) Patients with surgical contraindications before surgery, such as portal vein tumor thrombus and distant metastasis.
Key Trial Info
Start Date :
April 3 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 16 2025
Estimated Enrollment :
287 Patients enrolled
Trial Details
Trial ID
NCT06934070
Start Date
April 3 2025
End Date
April 16 2025
Last Update
April 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China, 330029